Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
ArriVent Announces Pricing of Upsized Initial Public Offering
Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA
Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing